Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Environmental Effects Type 1 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03102476
Recruitment Status : Completed
First Posted : April 5, 2017
Last Update Posted : October 31, 2018
Sponsor:
Information provided by (Responsible Party):
Thozhukat Sathyapalan, University of Hull

Tracking Information
First Submitted Date  ICMJE December 6, 2016
First Posted Date  ICMJE April 5, 2017
Last Update Posted Date October 31, 2018
Study Start Date  ICMJE June 2016
Actual Primary Completion Date February 2, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 30, 2017)
  • Area under the glucose infusion rate curve from 0 hours until the end of clamp. [ Time Frame: 1 Year ]
  • Onset of action, time from trial product administration until the blood glucose concentration has decreased at least 0.3 mmol/L (5 mg/dL) from the baseline [ Time Frame: I year ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 30, 2017)
  • Area under the glucose infusion rate curve from 0 hours until 2 hours [ Time Frame: 1 year ]
  • Area under the glucose infusion rate curve from 0 hours until 4 hours [ Time Frame: 1 year ]
  • Area under the glucose infusion rate curve from 0 hours until 6 hours [ Time Frame: 1 year ]
  • Area under the glucose infusion rate curve from 4 hours until 6 hours [ Time Frame: 1 year ]
  • Maximum glucose infusion rate [ Time Frame: 1 year ]
  • Time to maximum glucose infusion rate curve [ Time Frame: 1 year ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Environmental Effects Type 1 Diabetes Mellitus
Official Title  ICMJE A Study to Assess Environmental Effects of Temperature and Humidity on Pharmacokinetics and Pharmacodynamics of Prandial Insulin in Subjects With Type 1 Diabetes
Brief Summary

Type 1 Diabetes mellitus (T1D) is characterized by βcell destruction and a long life requirement of exogenous insulin. The bolus basal insulin regimen is a widely accepted therapy concept to treat hyperglycaemia in patients with T1D. This concept requires a very good knowledge of the individuals prandial and basal insulin requirements. However, insulin requirement depends on insulin absorption from the injection site and the individual's insulin sensitivity which relies on a number of effects including body composition, inflammatory processes and environmental factors. Climatic factors such as differences in air temperature could affect both, insulin absorption and insulin sensitivity as suggested by recent reports. For instance, it is reported that hot baths can accelerate the absorption of short acting but not of long acting insulin formulations from the subcutaneous depot. In addition, local warming of the injection site by a novel device (InsuPatch) results as well in an accelerated insulin action profile of short acting insulins. Moreover, Berglund et al. reported seasonal variations in insulin sensitivity in elderly men with increased insulin sensitivity during summer time.

Although an effect of temperature on insulin absorption and action can be assumed and was subject to current clinical trials, there is only little knowledge on the effect of humidity and the cumulative effect of humidity and temperature on insulin pharmacodynamics and pharmacokinetics. For subjects with type 2 diabetes it was reported that accommodation to high temperatures and moist air of more than 75% is impaired compared to healthy subjects as determined by skin blood flow, temperature and moisture. Although it can be estimated that changes in blood flow due to hot and moist air affect the pharmacokinetics and pharmacodynamics of subcutaneous prandial insulins, to our knowledge no such study in subjects with T1D using the euglycaemic clamp technique was carried out yet. In order to assess the effect of temperature and humidity on insulin action, subjects with type 1 diabetes will be administered a single dose of short acting insulin in an environmental chamber either at 15°C or a warm environment of 40°C with either a low or high humidity (10% vs. 90%). Moreover, an exploratory part of the trial will evaluate the measurement performance of several blood glucose meters under the experimental climatic situations.

Detailed Description

BACKGROUND Type 1 Diabetes mellitus (T1DM) is characterised by β-cell destruction and a lifelong requirement of exogenous insulin. The basal-bolus insulin regimen is widely accepted therapy to treat hyperglycaemia in patients with T1DM. This concept requires a very good knowledge of the individual's prandial and basal insulin requirements. However, insulin requirement depends on insulin absorption from the injection site and the individual's insulin sensitivity that relies on a number of factors including body composition, inflammatory processes and environmental factors. Environmental factors such as differences in air temperature could affect both, insulin absorption and insulin sensitivity as suggested by recent reports. For instance, it is reported that hot baths can accelerate the absorption of short-acting but not of long-acting insulin formulations from the subcutaneous depot. In addition, local warming of the injection site by a novel device (InsuPatch) results in an accelerated insulin-action profile of short-acting insulins. Moreover, Berglund et al. reported seasonal variations in insulin sensitivity in elderly men with increased insulin sensitivity during summer time.

Although an effect of temperature on insulin absorption and action can be assumed, there is only little knowledge on the effect of humidity and the cumulative effect of humidity and temperature on insulin pharmacodynamics and pharmacokinetics. For subjects with type 2 diabetes it was reported that accommodation to high temperatures and moist air of more than 75% is impaired compared to healthy subjects as determined by skin blood flow, temperature and moisture.

Although it can be estimated that changes in blood flow due to hot and moist air affect the pharmacokinetics and pharmacodynamics of subcutaneous prandial insulins, to our knowledge no such study in subjects with T1D using the euglycaemic clamp technique has been performed. In order to assess the effect of temperature and humidity on insulin action, subjects with type 1 diabetes will be given a single dose of short-acting insulin in an environmental chamber either at 15°C or a warm environment of 30°C with either a low or high humidity (10% vs. 60%).

TRIAL OBJECTIVES The objective of this trial is to assess the effect of different temperatures and humidity levels on the pharmacokinetic and pharmacodynamic profiles of short-acting insulin in subjects with type 1 diabetes mellitus.

TRIAL DESIGN The trial will be a single-centre, open label, 3-way cross-over, euglycaemic glucose clamp trial in subjects with type 1 diabetes mellitus. The pharmacodynamic and pharmacokinetic properties of insulin Humalog dosed at 0.2 U/kg will be investigated.

ENVIRONMENTAL SETTINGS

  • 15 °C and 10% humidity
  • 30 °C and 10% humidity
  • 30 °C and 60% humidity

ASSESSMENTS

  • 6 visits to the clinical unit: informed consent and screening visit (Visit 1, within 28 days prior to Visit 2a), Pre-dosing visit (Visit 2a, within 3 days of 2b), 3 dosing visits (Visit 2b, 3 & 4, wash-out period of 3-21 days between each visit), and 1 follow-up (FUP) examination (Visit 5, 3-14 days after last dosing visit)
  • Change in insulin regimen (72 hours prior to each dosing):

The patients will be switched from Insulin Lantus or detemir to NPH 48 hours before dosing visit. The NPH insulin will then be stopped 22 hours before dosing visit except short acting insulin which will be stopped 6-8 hours before visit.

  • Euglycaemic clamp setting for 6 hours after administration on dosing Visits 2b, 3 & 4
  • Blood to be collected for the determination of PK insulin concentrations on Visit 2b, 3 & 4 before and after administration of insulin
  • Blood glucose will be continuously monitored pre-administration and for 6 hours after administration of insulin
  • Determination of skin blood flow via Laser-Doppler
  • Standard safety parameters will be assessed throughout the study.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Type1diabetes
Intervention  ICMJE Drug: Humalog
Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
Other Name: Insulin lispro
Study Arms  ICMJE Patients with Type 1 Diabetes
Using euglycaemic clamp, the effect of different temperatures and humidity levels will be assessed on the pharmacokinetic and pharmacodynamic profiles of short-acting insulin Humalog.
Intervention: Drug: Humalog
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 30, 2017)
10
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE February 2, 2018
Actual Primary Completion Date February 2, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male subjects
  • Diabetes mellitus type 1
  • HbA1c ≤ 9.0 %
  • Total insulin dose of < 1.2 U/kg/day
  • Age between 18 and 55 years, both inclusive
  • Body mass index (BMI) between 18.0 and 28.0 kg/m2, both inclusive
  • Informed consent must be obtained for all volunteers in writing

Exclusion Criteria:

  • Known or suspected allergy to insulin.
  • Recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the Investigator or hospitalization for diabetic ketoacidosis during the previous 6 months.
  • Clinically significant diabetic neuropathy, in particular autonomous diabetic neuropathy.
  • Supine blood pressure at screening (after resting for 5 min in supine position) outside the range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial) and/or resting supine heart rate outside the range 50 -90 beats per minute. This exclusion criterion also pertains to subjects being on antihypertensives.
  • Treatment with any other investigational drug within 3 months prior to screening. Participation in a clinical research trial in last 3 months.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03102476
Other Study ID Numbers  ICMJE Version: 3.0 (02-07-2014)
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Thozhukat Sathyapalan, University of Hull
Study Sponsor  ICMJE University of Hull
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Thozhukat Sathyapalan, MD FRCP United Kingdom: Hull University
PRS Account University of Hull
Verification Date March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP